Dec 8, 20222 minDragonfly Therapeutics Announces First Patient Dosed in Phase 1 Study of its EGFR-targeting TriNKET™
Nov 1, 20222 minDragonfly Announces First Patient Dosed in Clinical Trial with Merck Evaluating Solid Tumor Target
May 1, 20221 minGilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engage
Mar 1, 20221 minBristol Myers partner comes through on IL-12 effort. Now it's Rupert Vessey's turn at bat
Nov 23, 20212 minDragonfly Therapeutics Announces Merck Opt-In of TriNKET™ Immunotherapy Candidate for Patients
Nov 9, 20213 minDragonfly Announces DF1001 Granted Orphan Drug Designation in the US for Esophageal Cancer
Oct 18, 20212 minDragonfly Therapeutics Announces Sixth Dragonfly Drug to be Licensed by Bristol Myers Squibb
Jan 12, 20212 minDragonfly Therapeutics Announces AbbVie Opt-In of TriNKET™ Immunotherapy Drug Candidate
Dec 10, 20202 minSpecial report: Twenty extraordinary women blazing trails in biopharma R&D — Covid-19 and beyond